Cellosaurus H3122 CR1 (CVCL_AY53)

Cell line name H3122 CR1
Accession CVCL_AY53
Resource Identification Initiative To cite this cell line use: H3122 CR1 (RRID:CVCL_AY53)
Comments Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori).
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_5160 (NCI-H3122)
Category Cancer cell line
Publications

PubMed=21502504; DOI=10.1073/pnas.1019559108
Katayama R., Khan T.M., Benes C., Lifshits E., Ebi H., Rivera V.M., Shakespeare W.C., Iafrate A.J., Engelman J.A., Shaw A.T.
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Proc. Natl. Acad. Sci. U.S.A. 108:7535-7540(2011)

PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846
Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.-Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C., Li J., Kasibhatla S., Sun F., Sun X., Hua S., McNamara P., Mahmood S., Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T., Engelman J.A.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Cancer Discov. 4:662-673(2014)